Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes

GLIA

Volumn 57, Issue 4, 2009, Pages 402-413

  Maier, Olaf ^a,b   De Jonge, Jenny ^a   Nomden, Anita ^a   Hoekstra, Dick ^a   Baron, Wia ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Cholesterol synthesis; Isoprenylation; Multiple sclerosis; Myelin formation; Statins

Indexed keywords

FARNESYL DIPHOSPHATE; GALACTOSPHINGOLIPID; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; PROTEOLIPID PROTEIN; RO 48 8071; SPHINGOLIPID; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; IN SITU HYBRIDIZATION; MYELIN SHEATH; MYELINATION; NEUROTOXICITY; NEWBORN; NONHUMAN; OLIGODENDROGLIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PRENYLATION; PROTEIN TRANSPORT; RAT; RNA TRANSPORT; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BENZOPHENONES; CELL MEMBRANE; CELL SURVIVAL; CHOLESTEROL; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; OLIGODENDROGLIA; PHOSPHATES; POLYISOPRENYL PHOSPHATES; PROSENCEPHALON; PROTEIN TRANSPORT; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 66149089362     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20769     Document Type: Article

References (54)

1. Barbarese E, Koppel DE, Deutscher MP, Smith CL, Ainger K, Morgen F, Carson JH. 1995. Protein translation components are colocalized in granules in oligodendrocytes. J Cell Sci 108:2781-2790.
2. Björkhem I, Meaney S. 2004. Brain cholesterol: a secret life behind a barrier. Arterioscler Thromb Vasc Biol 24:806-815.
3. Böttcher CJF, van Gent CM, Pries C. 1961. A rapid and sensitive submicro phosphorus determination. Anal Chim Acta 24:203-204.
4. Bouverat BP, Krueger WH, Coetzee T, Bansal R, Pfeiffer SE. 2000. Expression of rab GTP-binding proteins during oligodendrocyte differentiation in vitro. J Neurosci Res 59:446-453.
5. Brown PE, de Angelis D, Shtybel WW, Bernier L. 1991. Isoprenoid modification permits 2′,3′-cyclic nucleotide 3′-phosphodiesterase to bind to membranes. J Neurosci Res 30:540-544.
6. Brück W. 2005. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 252 (Suppl 5):v3-v9.
7. Brück W, Kuhlmann T, Stadelmann C. 2003. Remyelination in multiple sclerosis. J Neurol Sci 206:181-185.
8. Burcelin R, Rodriguez-Gabin AG, Charron MJ, Almazan G, Larocca JN. 1997. Molecular analysis of the monomeric GTP-binding proteins in oligodendrocytes. Brain Res Mol Brain Res 50:9-15.
9. Buttery PC, ffrench-Constant C. 1999. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. Mol Cell Neurosci 14:199-212.
10. Carson JC, Worboys K, Ainger K, Barbarese E. 1997. Translocation of myelin basic protein mRNA in oligodendrocytes requires microtubules and kinesin. Cell Motil Cytoskeleton 38:318-328.
11. DeBruin LS, Harauz G. 2007. White matter rafting - membrane microdomains in myelin. Neurochem Res 32:213-228.
12. De Vries H, de Jonge JC, Schrage C, van der Haar M, Hoekstra D. 1997. Differential and cell development-dependent localization of myelin mRNAs in oligodendrocytes. J Neurosci Res 47:479-488.
13. Fitzner D, Schneider A, Kippert A, Möbius W, Willig KI, Hell SW, Bunt G, Gaus K, Simons M. 2006. Myelin basic protein-dependent plasma membrane reorganization in the formation of myelin. EMBO J 25: 5037-5048.
14. Galiano MR, Andrieux A, Deloulme JC, Bosc C, Schweitzer A, Job D, Hallak ME. 2006. Myelin basic protein functions as a microtubule stabilizing protein in differentiated oligodendrocytes. J Neurosci Res 84:534-541.
15. Gamble W, Vaughan M, Kruth HS, Avignan J. 1978. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19: 1068-1070.
16. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL, Pasini FL, Baldari CT. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of ras superfamily GTPases. FASEB J 19:605-607.
17. Gielen E, Baron W, Vandeven M, Steels P, Hoekstra D, Ameloot M. 2006. Rafts in oligodendrocytes: Evidence and structure-function relationship. Glia 54:499-512.
18. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343:425-430.
19. Greenwood J, Steinman L, Zamvil SS. 2006. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 6:358-370.
20. Grigoriev I, Splinter D, Keijzer N, Wulf PS, Demmers J, Ohtsuka T, Modesti M, Maly IV, Grosveld F, Hoogenraad C, Akhmanova A. 2007. Rab6 regulates transport and targeting of exocytotic carriers. Dev Cell 13:305-314.
21. Hall A. 2005. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 33:891-895.
22. Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A. 2006. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis. Ann Neurol 60:45-55.
23. Jordens I, Marsman M, Kuijl C, Neefjes J. 2005. Rab proteins, connecting transport and vesicle fusion. Traffic 6:1070-1077.
24. Jung M, Sommer I, Schachner M, Nave KA. 1996. Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): Evidence that PLP misfolding underlies dysmyelination in mutant mice. J Neurosci 16:7920-7929.
25. Kuipers HF, van den Elsen PJ. 2007. Immunomodulation by statins: Inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother 61:400-407.
26. Kwak B, Mulhaupt F, Myit S, Mach F. 2000. Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402.
27. Laezza C, Wolff J, Bifulco M. 1997. Identification of a 48-kDa prenylated protein that associates with microtubules as 2′,3′-cyclic nucleotide 3′-phosphodiesterase in FRTL-5 cells. FEBS Lett 413:260-264.
28. Lee J, Gravel M, Zhang R, Thibault P, Braun PE. 2005. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly protein. J Cell Biol 170:661-673.
29. Liang X, Draghi NA, Resh MD. 2004. Signaling from fyn to rho family GTPases regulates morphologic differentiation of oligodendrocytes. J Neurosci 24:7140-7149.
30. Locatelli S, Lütjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. 2002. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesteremia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59:213-216.
31. Maier O, Baron W, Hoekstra D. 2008. Polarity development in oligodendrocytes: Sorting and trafficking of myelin components. J Mol Neurosci 35:35-53.
32. Maier O, van der Heide T, van Dam AM, Baron W, de Vries H, Hoekstra D. 2005. Alteration of the extracellular matrix interferes with raft-association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? Mol Cell Neurosci 28:390-401.
33. März P, Otten U, Miserez AR. 2007. Statins induce differentiation and cell death in neurons and astroglia. Glia 55:1-12.
34. McTaggart SJ. 2006. Isoprenylated proteins. Cell Mol Life Sci 63:255-267.
35. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP 2007. Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55:130-143.
36. Morand OH, Aebi JD, Dehmlow H, Ji YH, Gains N, Lengsfeld H, Himber J. 1997. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res 38:373-390.
37. Morell P, Jurevics H. 1996. Origin of cholesterol in myelin. Neurochem Res 21:463-470.
38. Olsen IM, ffrench-Constant C. 2005. Dynamic regulation of integrin activation by intracellular and extracellular signals controls oligodendrocyte morphology. BMC Biol 3:25
39. Paintha AS, Paintlia ME, Khan M, Vollmer T, Singh AK, Singh I. 2005. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 19:1407-1421.
40. Paintlia AS, Paintlia MK, Singh AK, Singh I. 2008. Inhibition of Rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 73: 1381-1393.
41. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka. H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165-3172.
42. Peterson LE, Fujinami RS. 2007. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 183:69-80.
43. Ranscht B, Clapshaw PA, Price J, Noble M, Seifert W. 1982. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactosylcerebroside. Proc Natl Acad Sci USA 79:2709-2713.
44. Saheki A, Terasaki T, Tamai I, Tsuji A. 1994. In vivo and in vitro bloodbrain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11:305-311.
45. Saber G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. 2005. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:468-475.
46. Seabra MC. 1998. Membrane association and targeting of prerylated ras-like GTPases. Cell Signal 10:167-172.
47. Sena A, Pedrosa R, Morais MG. 2003. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 250:754-755.
48. Sim FJ, Lang JK, Ali TA, Roy NS, Vates GE, Pilcher WH, Goldman SA. 2008. Statin treatment of adult human glial progenitors induces PPARγ-mediated oligodendrocytic differentiation. Glia 56:954-962.
49. Simons M, Krämer EM, Thiele C, Stoffel W, Trotter J. 2000. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J Cell Biol 151:143-154.
50. Simons M, Trotter J. 2007. Wrapping it up: The cell biology of myelination. Curr Opin Neurobiol 17:533-540.
51. Stanislaus R, Gilg AG, Singh AK, Singh I. 2002. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rat by lovastatin. Neurosci Lett 133:167-170.
52. Trajkovic K, Dhaunchak AS, Goncalves JT, Wenzel D, Schneider A, Bunt G, Nave KA, Simons M. 2006. Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. J Cell Biol 172:937-948.
53. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Pleiningerova J, Rizzo M, Singh I. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608.
54. Youssef S, Struve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84.